Compare Arko Corp. (ARKO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? Arko Corp. trades at $4.37 (market cap $493.06M), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Arko Corp. pays a 2.73% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Arko Corp. nearer its low. Which is the better fit depends on your goals.
| ARKO | XBI | |
|---|---|---|
Market Cap | $493.06M | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $8.64 | $164.28 |
52-Week Low | $3.82 | $86.92 |
Enterprise Value | $2.67B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO trades at $4.46, down 5.11% on the day, reflecting bearish technical signals and recent earnings miss. The company maintains a low P/S ratio of 0.06 and pays consistent dividends, but faces declining revenue and thin net margins. Recent news highlights weak Q2 2026 results and softer retail demand, with analysts holding a neutral stance.
Outlook remains cautious due to earnings volatility and competitive pressures, though the dividend yield and low valuation offer some value. Key risks include consumer spending sensitivity and high debt levels, requiring close monitoring of margin defense strategies and fuel pricing discipline for recovery.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
